Company intelligence / Profile preview
JN Nova Pharma
Amos, Quebec, Canadajnnova.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
JN Nova Pharma has completed GMP manufacturing and toxicology studies and is preparing the Clinical Trial Application package for Phase I studies for Long COVID treatment. Their lead product JN2019/KG2019 has shown ability to neutralize SARS-CoV-2 variants of concern, including Omicron.
- Therapeutic areas
- NephrologyPulmonologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
National Research Council CanadaCanadian Government labsCanadian academic centers
Beyond the preview
Go deeper on JN Nova Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JN Nova Pharma.